Royal College of Physicians

ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

Retrieved on: 
Monday, January 22, 2024
Bristol Myers Squibb, Neurophysiology, Patient, MD, Sanjay, Medicine, St Bartholomew's Hospital, Johns Hopkins Hospital, Johns Hopkins, Royal College of Physicians, Immunology, Saint Mary's Hospital, Acquisition, Royal college, Bachelor of Science, CMO, IPO, Bartholomew the Apostle, Fibrosis, Hospital, Series A round, FRCP, Roche, Faricimab, Growth, Pharmaceutical industry

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
  • Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies.
  • "As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain," stated Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain.
  • I am privileged to work with the ImmunoBrain team and Professor Michal Schwartz whose groundbreaking seminal research has formed the foundation of ImmunoBrain," stated Dr. Sanjay Keswani.

CDR-Life Announces Appointment of Swethajit Biswas, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, August 23, 2022
Partnership, University, Royal college, Cancer, F.X. v The Clinical Director of Central Mental Hospital and Another, FRCP, National Health Service, Time, Doctor of Philosophy, Multiple myeloma, Severe cognitive impairment, GSK, Royal College of Physicians, Geographic atrophy, LinkedIn, Newcastle, MHC, Antigen, NHS, BCMA, GlaxoSmithKline, Brain, GLOBE, Company, Biotechnology, Therapy, Twitter, Boehringer Ingelheim, Cancer/testis antigens, Sarcoma, Oncology, TCR, Patient, Lymphoma, Fine chemical, Pharmaceutical industry, MD

Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.

Key Points: 
  • Prior to joining CDR-Life, Dr. Biswas was a Development Leader for MAGE-A4+ autologous cell therapies at Adaptimmune Therapeutics plc, progressing afamitresgene autoleucel through an accelerated approval submission pathway.
  • He also held an academic position as a Clinical Senior Lecturer in medical oncology at Newcastle Universitys Northern Institute for Cancer Research (NICR) from 2009 to 2013.
  • Dr. Biswas received his medical degree from Sheffield University Medical School and his DPhil from the University of Oxford.
  • For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

Retrieved on: 
Tuesday, July 5, 2022
Patient, School, Nose, Legislation, BMS, Kingdom, COVID-19, Growth, Company, CRS, Pharmacotherapy, SVP, Doctor of Philosophy, Pharmacy, Drug development, Movement disorders, Royal College of Physicians, Therapy, SVP Worldwide, King's College, Thrombosis, Immunology, FDA, Migraine, Tissue, Paranasal sinuses, ENT, Medicine, Teva, Risk, Specialty, Bayer, Twitter, Neman, LinkedIn, CEO, Inflammation, Failure, Multiple sclerosis, Bristol Myers Squibb, Private Securities Litigation Reform Act, Ear, Nasdaq, Public health, Leadership, LYRA, Stroke, Sinusitis, Employment, Terrorism, Lists of disasters, Asthma, MD, Pharmaceutical industry, Lyra, Industry, Physician

WATERTOWN, Mass., July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Richard Nieman, MD, has been appointed Chief Medical Officer, effective July 11, 2022. Dr. Nieman brings more than 25 years of experience in drug development and medical affairs, with a proven track record in developing medicines through commercialization and beyond.

Key Points: 
  • (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Richard Nieman, MD, has been appointed Chief Medical Officer, effective July 11, 2022.
  • "We're pleased to welcome Dr. Nieman as our Chief Medical Officer," said Maria Palasis, PhD, CEO of Lyra Therapeutics.
  • "Dr. Nieman joins the Lyra team at a critical time with our lead candidate LYR-210 in pivotal Phase 3 trials.
  • Nieman assumes the role of Chief Medical Officer previously held by Dr. Robert Kern, who will continue to work closely with the Company in the role of Chief Clinical Advisor.

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

Retrieved on: 
Monday, June 27, 2022
Biostatistics, Shire (pharmaceutical company), HPV, University, Business administration, Henley Business School, Cancer, CMO, Infection, MBA, Novo Nordisk, Pharmacovigilance, DNA, Royal College of Physicians, NASDAQ, Novartis, Royal college, MB, Vaccine, Medical device, Physician

PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO).

Key Points: 
  • PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO).
  • Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs.
  • He will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Officer, Dr. Jacqueline Shea.
  • INOVIO's President and Chief Executive Officer, Jacqueline Shea, Ph.D., said, "INOVIO is pleased to welcome Dr. Sumner to INOVIO.

Sitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer

Retrieved on: 
Tuesday, April 12, 2022
Faculty of Pharmaceutical Medicine, University of Cambridge, Therapy, Company, Faculty, GSK, LinkedIn, Metabolism, Royal college, Degenerative disease, Leadership, Immunometabolism, Sofinnova, Lilly, Group medical practice in the United States, Biotechnology, Head, MB, Cancer, Pharmaceutical medicine, Royal College of Physicians, Roche, GlaxoSmithKline, Oxford BioMedica, Imperial College London, Doctor of Philosophy, Harvard Medical School, Eli Lilly and Company, Lists of diseases, The Company, Development, DBV Technologies, Patient, Disease, Research and development, Pharmaceutical industry, Physician, Research

OXFORD, England, April 12, 2022 /PRNewswire/ --Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced the appointment of Dr. Ravi M. Rao as its Chief Medical Officer.

Key Points: 
  • OXFORD, England, April 12, 2022 /PRNewswire/ --Sitryx Therapeutics Ltd (the "Company"), a biopharmaceutical company pioneering the field of immunometabolism, today announced the appointment of Dr. Ravi M. Rao as its Chief Medical Officer.
  • "We are delighted to appoint Ravi to this new role of Chief Medical Officer at Sitryx.
  • Dr. Rao joins Sitryx from Swedish Orphan Biovitrum, where he served as Head of Research and Development and Chief Medical Officer leading the development of several medicines in rare diseases across immunology and haematology.
  • Prior to that, he was Chief Medical Officer of Aeglea Biotherapeutics, a company specialising in rare metabolic diseases.

MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease

Retrieved on: 
Tuesday, March 8, 2022
Doctor of Philosophy, Johns Hopkins, Imperial College London, Patient, MBA, GLOBE, Johns Hopkins Hospital, Office of Rare Diseases Research, Royal College of Physicians, Biotechnology, Hospital, BTLA, Roche, PD-1, University, Chief medical informatics officer, Duloxetine, FRCP, Degenerative disease, MBBS, Research and development, UCLA, Disease, Development, Medicine, CEO, Faricimab, Royal college, Head, Autoimmune disease, Cell, Autoimmunity, Neurology, Health, Publication, Pathology, Regeneration, Management, Pharmaceutical industry, Vaccine, Research, Physician, Pharmacology, Janssen, Neuroscience, Ophthalmology

We are thrilled to have Sanjay and Lynne join MiroBios executive leadership team as we advance a potentially transformative therapeutic approach for patients suffering from autoimmune diseases, said Dr. Carolin Barth, M.D., CEO of MiroBio.

Key Points: 
  • We are thrilled to have Sanjay and Lynne join MiroBios executive leadership team as we advance a potentially transformative therapeutic approach for patients suffering from autoimmune diseases, said Dr. Carolin Barth, M.D., CEO of MiroBio.
  • MiroBios inhibitory receptor agonist approach represents a promising new mode of action for treating these complex diseases.
  • With our enhanced leadership team, we look forward to moving our therapies into the clinic and delivering our ultimate goal of providing durable remission to patients with autoimmune diseases.
  • MiroBio is creating a new class of therapies for autoimmune disease: Checkpoint agonist antibodies.

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

Retrieved on: 
Friday, October 29, 2021
Dermatology, Merck, CH, University of Lausanne, Public policy, GB, Gebert, COVID-19, University of St. Gallen, Acquisition, GLOBE, Neurodegeneration, HIV, Diagnosis, Physician, Swiss National Bank, Honorary degree, RU, Company, World Bank, JP, Leo Pharma, Science, Neurology, AU, Industry, Royal college, University of Zurich, Medical director, NO, Drug development, AC, 2007 Swiss Federal Council election, Genentech, Eli Lilly and Company, Precision medicine, World, Royal College of Physicians, Janssen Pharmaceuticals, EGM, Board of directors, Federal Council, University, Hoffmann-La Roche, NASDAQ, Â, Novartis, Board, Schindler Elevator Corporation, Medical device, Management, Pharmaceutical industry, Medicine

LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.

Key Points: 
  • Dr. Shaw and Prof. Btler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.
  • We also extend our sincere thanks to Mr. Velasco and Dr. Bollmann, as their contributions as Directors helped to establish AC Immunes position as an industry leader.
  • I look forward to working with my fellow Directors to provide valuable insights and guidance as the Company advances its industry-leading strategy.
  • SupraAntigen is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP and RU.

Certara Announces New Clinical Science Group and Adds Senior Scientific Experts

Retrieved on: 
Wednesday, September 22, 2021
GlaxoSmithKline, US-China Strategic Engagement, Biocuration, IDD, Therapy, Medical Research Council, Clinical pharmaceutical scientist, Senior advisor, Global Health, American Association, National Health, Decision-making, White House, Royal college, Association, Physician, Novo Nordisk, Faculty, Senior, Bill, Consultant, Hematology, Company, Science Council, Pharmacology, Royal College of Physicians, Global health, Technology, Reproducibility, Drug development, Drug discovery, Amgen, Clinical research, Industry, Society, GLOBE, Management, Pharmaceutical industry

The Company also appointed David Mitchell, Ph.D., as Senior Vice President of Strategic Engagement and added C. Glenn Begley M.D., Ph.D., and Colin Pillai, Ph.D., as Senior Scientific Advisors.

Key Points: 
  • The Company also appointed David Mitchell, Ph.D., as Senior Vice President of Strategic Engagement and added C. Glenn Begley M.D., Ph.D., and Colin Pillai, Ph.D., as Senior Scientific Advisors.
  • Modern drug development is a team sport, and with the new clinical science group and these appointments, Certara will further advance our strategic partnerships and help train talent in model-informed drug development, saidCraig R. Rayner, President, Integrated Drug Development at Certara.
  • At Certara, Dr. Marshall will be responsible for establishing and growing the clinical science group of senior level scientists and physicians, which will drive clinical and medical elements of Certaras consulting offerings to clients.
  • At Certara, Dr. Begley will contribute to translational medicine, a key clinical science capability.

Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

Retrieved on: 
Friday, September 10, 2021

This webinar will feature presentations from KOLs Jaume Mora, M.D., Ph.D., SJD Barcelona Children's Hospital, and Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering.

Key Points: 
  • This webinar will feature presentations from KOLs Jaume Mora, M.D., Ph.D., SJD Barcelona Children's Hospital, and Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering.
  • Shakeel Modak, M.D., MRCP is a pediatric hematology-oncology doctor at Memorial Sloan Kettering Cancer Center, Department of Pediatrics in New York.
  • degrees from TN Medical College, Bombay, as well as his MRCP degree from Royal College of Physicians, London.
  • Dr. Modak specializes in the treatment of children and young adults with neuroblastoma and other solid tumors, such as DSRCT.

The Federation of Royal Colleges of Physicians Approves UpToDate Clinical Decision Support for CPD

Retrieved on: 
Tuesday, April 20, 2021
General Health, Health, Continuing, University, Education, London boroughs, London Borough of Camden, Royal College of Physicians and Surgeons, Wolters Kluwer, Royal College of Physicians, Royal College, College of Physicians and Surgeons, UpToDate, Faculty of Pharmaceutical Medicine

b'UpToDate, the clinical decision support tool from Wolters Kluwer, Health has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom as a continuing professional development (CPD) activity.

Key Points: 
  • b'UpToDate, the clinical decision support tool from Wolters Kluwer, Health has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom as a continuing professional development (CPD) activity.
  • The organization is a collaboration between the Royal College of Physicians of London, Royal College of Physicians of Edinburgh, and Royal College of Physicians and Surgeons of Glasgow.
  • CPD credits are earned from UpToDate by consulting information relevant to a specific clinical question, thus broadening clinical knowledge.\nUpToDate will provide physicians and surgeons with quick and easy access to evidence-based clinical topics and recommendations.
  • We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions.